Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes
Status:
Recruiting
Trial end date:
2027-02-13
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test whether the combination of two safe immune
therapies called abatacept and nasal insulin can preserve pancreas function in
recently-diagnosed type 1 diabetes. When type 1 diabetes is first diagnosed, the pancreas is
still able to make small amounts of insulin, which helps control glucose levels. Preserving
pancreas function can make glucose control easier and reduce the need to use injected
insulin.
Participants will be asked to inject abatacept under their skin once per week and inhale
nasal insulin or nasal placebo using a spray for 10 consecutive days initially and twice per
week thereafter. The treatment period is for 48 weeks, with another 48-week follow-up period.
Phase:
Phase 2
Details
Lead Sponsor:
Melbourne Health
Collaborators:
Juvenile Diabetes Research Foundation National Health and Medical Research Council, Australia